Skip to content
AnimalSelective cancer cell membrane-targeting peptide

PNC-27

Also indexed as PNC27, p53-derived peptide, HDM-2 targeting peptide

PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, designed to selectively induce apoptosis in cancer cells while leaving normal cells unharmed. It contains an MDM-2-binding domain of p53 fused to a transmembrane-penetrating sequence, enabling it to insert into the membranes of cancer cells that aberrantly express HDM-2 on their surface. Research has been conducted primarily in vitro and in animal models, with very limited human data available.

Overview

Pharmacokinetically, PNC-27 is a mid-sized peptide (~3.8 kDa) subject to rapid proteolytic degradation in plasma, giving it a short estimated half-life. Its selectivity depends entirely on differential HDM-2 surface expression between malignant and normal cells. In vitro studies demonstrate activity against pancreatic adenocarcinoma, breast carcinoma, melanoma, and leukemic cell lines. Normal fibroblasts and endothelial cells show significantly reduced susceptibility. In rodent xenograft models, intratumoral and systemic administration has shown tumor regression with acceptable tolerability, though full pharmacokinetic and toxicokinetic profiling in humans is absent.

Proposed mechanism

PNC-27 targets HDM-2 (human double minute 2 protein), which is overexpressed on the plasma membrane surface of various cancer cells but absent on normal cells. Upon binding to membrane-resident HDM-2, PNC-27 inserts into the cancer cell membrane and forms pores, leading to rapid necrotic cell death via membrane disruption rather than the slower intrinsic apoptotic pathway. Normal cells lacking surface HDM-2 expression are largely spared from this cytotoxic mechanism.

What the evidence supports

Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Graded Animal

Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Selective tumor cell killing by a p53-derived peptide through membrane HDM-2 binding

    · Bowne WB, et al. Annals of Surgical Oncology, 2007 · 2007

  2. [2]

    PNC-27, a p53-derived peptide, induces tumor cell killing in both p53 wild type and mutant cell lines

    · Riel-Mehan MM, et al. Cancer Biology & Therapy · 2008

  3. [3]

    HDM-2 on the surface of tumor cells mediates PNC-27-induced tumor cell necrosis

    · Zetter BR et al., related research in Journal of Biological Chemistry · 2012

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.

Related profiles

ACTH 1-39

Clinical

Full-length adrenal hormone with broad receptor activity

ACTH 1-39 is the full-length, biologically active form of adrenocorticotropic hormone, a 39-amino acid peptide naturally secreted by the anterior pituitary gland. It primarily stimulates the adrenal cortex to produce cortisol, aldosterone, and adrenal androgens. Beyond adrenal signaling, ACTH 1-39 exerts direct effects on the brain, immune system, and peripheral tissues via melanocortin receptors.

0 RCT · 0 human · 0 preclinical

Immune

Adipotide (FTTP)

Animal

Targeted fat-depot destruction via vascular apoptosis

Adipotide (also called FTTP) is an experimental peptidomimetic compound designed to selectively destroy the blood supply to white adipose tissue by targeting prohibitin, a protein highly expressed on the vasculature feeding fat cells. Originally developed at MD Anderson Cancer Center, it demonstrated dramatic fat loss in obese rhesus monkeys without dietary restriction. It remains a research compound with no approved human clinical use.

0 RCT · 0 human · 0 preclinical

fat-loss

AICAR

Human-limited

AMPK activator mimicking endurance exercise effects

AICAR (Acadesine) is a nucleoside analog and potent AMPK activator that mimics the cellular energy-depletion state, triggering a cascade of metabolic adaptations including enhanced fatty acid oxidation and mitochondrial biogenesis. It has been extensively studied for its ability to improve endurance performance, insulin sensitivity, and metabolic flexibility without physical exercise. Originally developed as a cardioprotective agent, it has attracted significant interest in the performance and longevity research communities.

0 RCT · 0 human · 0 preclinical

metabolic